The Dutch chronic lower limb-threatening ischemia registry

• Published in: PloS one Vol. 18; no. 7; p. e0288912
• Main Authors: Nugteren, Michael J, Hazenberg, Constantijn E. V. B, Akkersdijk, George P, Bakker, Olaf J, Dinkelman, Maarten K, Fioole, Bram, van den Heuvel, Daniel A. F, Heyligers, Jan M. M, Hinnen, Jan-Willem, Pierie, Maurice, Schouten, Olaf, Schreve, Michiel A, Verhoeven, Bart A. N, de Borst, Gert J, Ünlü, Çagdas
• Format: Journal Article
• Language: English
• Published: Public Library of Science 20-07-2023
• Subjects: Analysis; Care and treatment; Complications and side effects; Diagnosis; Ischemia; Peripheral vascular diseases; Prevention; Registries (in medicine); Risk factors; Netherlands
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0288912

Chronic limb-threatening ischemia (CLTI) is the end stage of peripheral arterial disease (PAD) and is associated with high amputation rates, mortality and disease-related health care costs. In infrapopliteal arterial disease (IPAD), endovascular revascularization should be considered for the majority of anatomical and clinical subgroups of CLTI. However, a gap of high-quality evidence exists in this field. The aim of the Dutch Chronic Lower Limb-Threatening Ischemia Registry (THRILLER) is to collect real world data on popliteal and infrapopliteal endovascular interventions. THRILLER is a clinician-driven, prospective, multicenter, observational registry including all consecutive patients that undergo a popliteal or infrapopliteal endovascular intervention in seven Dutch hospitals. We estimate that THRILLER will include 400-500 interventions annually. Standardized follow-up visits with wound monitoring, toe pressure measurement and duplex ultrasonography will be scheduled at 6-8 weeks and 12 months after the intervention. The independent primary endpoints are primary patency, limb salvage and amputation free survival. Patients must give informed consent before participation and will be included according to predefined reporting standards. A data log of patients who meet the inclusion criteria but are not included in the registry will be maintained. We intend to conduct the first interim analysis two years after the start of inclusion. The results will be published in a scientific journal. Despite innovations in medical therapy and revascularization techniques, patients with CLTI undergoing endovascular revascularization still have a moderate prognosis. Previous prospective cohort studies were hampered by small sample sizes or heterogeneous reporting. Randomized controlled trials (RCTs) have high costs, potential conflicts of interest and give a limited reflection of daily practice. THRILLER aims to provide the largest prospective well phenotyped up-to-date dataset on treatment outcomes in CLTI patients to answer multiple underexplored research questions regarding diagnostics, medication, patient selection, treatment strategies and post intervention follow-up.